Integrase genotypic resistance analysis was performed in all subjects from amino acids 53 to 288. Integrase Sanger sequencing was conducted according to the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS) consensus method as previously described. 1 The subtype determination was performed using the Module HIV from SmartGeneV R (Zug, Switzerland) whose methodology is based on BLAST. UDS was performed by using GSJunior platform according to manufacturer recommendations in both clinical centres as previously described. An amplicon variant analyser was used to analyse the UDS data, with a detection threshold of MRV of 2% (forward and reverse).
Resistance was interpreted according to the last version of the ANRS algorithm (www.hivfrenchresistance.org). The mutational load was considered as the number of mutated copies/mL (product of percentage of a mutation by viral load).
An average of 3464 reads per nucleotide position was amplified. Characteristics of patients are presented in Table 1 . Viruses of seven patients harboured majority resistant variants by Sanger sequencing (five L74I and two E157Q mutations). In three patients, viruses harboured MRVs detected by UDS only: two R263K mutations (at a rate of 9.7% the mutational load is 7099 copies/mL, and at 13.5% the mutational load is 8345 copies/mL, in the presence of a L74I mutation detected by both techniques) and one E138K mutation (at 4.8%, 111 copies/mL). All these mutations were retrieved/detected among MSM patients infected by a subtype B virus.
None of the three classical ISTI signature resistance mutations (at positions 143, 148 and 155) was retrieved. However, among MSM treatment-naive patients, the prevalence of ISTI-associated resistance mutations seems to be relatively high [10.0% by Sanger (95% CI: 3.0%-17.0%) and 14.3% by UDS (95% CI: 6.1%-22.5%)]. Moreover, our results are consistent with what has been previously shown by Sanger sequencing in the study on French patients diagnosed at the time of primary HIV-1 infection in which the E157Q first generation ISTI mutation, was detected in 5 of 331 cases (1.5%). 4 Indeed, mutations detected by Sanger sequencing (E157Q, L74I) are known to be mainly related to polymorphism in databases, whereas mutations detected by UDS only (E138K, R263K) are not. 5, 6 By querying a large Italian anonymous database including 1307 integrase plasma Sanger sequences from HIV-1-infected drug-naive patients, the R263K mutation was detected only in five samples (0.4%), often as a mixture with the WT virus R263R (D. Armenia, M. M. Santoro, D. Di Carlo, C. Gori, A. Bertoli, V. Borghi, F. Ceccherini-Silberstein, C. Mussini, M. Andreoni, A. Antinori and C. F. Perno, University of Rome Tor Vergata, unpublished results). In vivo, the R263K mutation had been described in experienced but also in ISTI-naive patients failing a dolutegravir once daily regimen. 7, 8 This mutation had been described as a dolutegravir resistance-associated mutation selected in cell culture with a negative impact on viral fitness. 9 This unfavourable impact might explain why the R263K mutation was detected only by UDS as a minority species in two patients in our study, whose viruses are not phylogenetically related (genetic distance .8% between sequences). Indeed, we can suppose that the low viral fitness related to this mutation avoids the spread of these variants among intra-patient quasispecies.
Furthermore, in our current dataset, one patient with R263K harboured the TDR mutation K103N in the reverse transcriptase gene. This patient was the only one who has initiated an integrase inhibitor-based regimen (tenofovir, emtricitabine and raltegravir) among patients with mutated viruses. Nevertheless, the virological outcome was a success with a viral load ,50 copies/mL after 3, 6 and 12 months under this treatment. Indeed, in vitro, R263K mutants obtained by side-directed mutagenesis were hypersensitive to raltegravir (fold-change from 0.5 to 0.8). 10 In conclusion, with the increased use of ISTI in clinical practice, the presence of ISTI-associated resistance mutations in naive patients should be considered in the future, and our results suggest that integrase pre-treatment genotypic analysis might be useful. However, the impact of integrase MRVs should be further studied. n " 7; 7.6% (2.2%-13.0%)
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